Pulmonary Drug Delivery Systems Market Overview
"The Pulmonary Drug Delivery Systems Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031."
The inhalation route is a fast and effective way of delivering medication, both locally to the lungs and to the body. The pulmonary route is used to treat various respiratory diseases. The pulmonary route has gained increasing importance due to its unique properties such as a large absorptive area, extremely thin absorptive mucosal membrane and good blood supply.
Pulmonary drug delivery can be used as an alternative to oral delivery. Pulmonary route provides enhanced bioavailability, reduced toxic effect and targeted means of delivery. Advantages of pulmonary drug delivery are needle free, requires low oral dose, negligible side effects, and onset of action is very quick.
Pulmonary drug delivery is use to treatment of illnesses including asthma, chronic obstructive pulmonary disease and various other diseases.
The key driver of pulmonary drug delivery systems market is rising prevalence of chronic respiratory disorders such as tuberculosis, bronchitis and chronic obstructive pulmonary disease. In addition, technological advancements such smart inhaler, changing lifestyle, increase in smoking, limitations of traditional treatments for pulmonary delivery, better penetrability of drug, minimum dosage requirement are factors boosting demand for pulmonary drug delivery systems. However, regulatory hurdles, patent expiration of blockbuster drugs is expected to hinder growth of the global market.
Growing adoption of pulmonary drug delivery as an alternative to route of drug delivery, the market is gaining traction due to development of smart and digital inhalers, increasing number of smokers, and growth of the distribution network.
According to the World Health Organization, global chronic obstructive pulmonary disease (COPD) prevalence are 251 million cases in 2016. Nanoparticles (NPs) are emerging effective targeted drug delivery systems because of their non-invasive approach and lesser bioavailability in the systemic circulation.
North America market is estimated to dominate the global pulmonary drug delivery systems market, owing to increase growing prevalence of lung and respiratory diseases, which is expected to boost growth of the market in this region. Asia Pacific market is the emerging market for pulmonary drug delivery systems market due to presence of various players focusing on the development of inhaler products and entering untapped market.
Global Pulmonary Drug Delivery Systems Market Segmentation:
Segmentation based on product:
- Dry Powder Inhalers
- Single-Dose Inhalers
- Multi-Dose Inhaler
- Metered Dose Inhaler
- Manually-Actuated Pressurized Inhaler
- Breath-Actuated Pressurized Inhaler
- Jet Nebulizers
- Ultrasonic Wave Nebulizers
- Vibrating Mesh Nebulizer
Segmentation based on application:
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Others (including cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators)
Segmentation based on distribution channel:
- Retail pharmacy
- Hospital pharmacy
Segmentation based on region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Sunovion Pharmaceuticals Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim GmbH
- Omron Healthcare, Inc.
- Skyepharma Plc
- CareFusion Corporation
- Philips Respironics Inc.
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!